Trial | NCT00132626  Report issue

Title

Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome
Dynamic SPECT Imaging With [123I]ß-CIT in Patients With Parkinsonism

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    500
This study assesses dopamine transporter density using single photon emission computed tomography (SPECT) brain imaging with an investigational radiopharmaceutical, [123I]ß-CIT, in research participants with Parkinson's disease.
The brain imaging is conducted at the Institute for Neurodegenerative Disorders in New Haven, Connecticut. The imaging procedure occurs over a two day period.

After a screening visit, including review of the potential subject's neurological history and a thorough neurologic exam, subjects are injected with [123I]ß CIT, an investigational radioactive material that localizes in the brain.

Twenty-four hours later study participants return to the Institute for Neurodegenerative Disorders where an investigational scanning procedure is used to obtain SPECT (single photon emission computed tomography) images of the brain.
Study Started
Sep 30
1992
Study Completion
Aug 31
2005
Last Update
Apr 03
2019

Criteria 

Inclusion Criteria:

At least 21 years of age
Normal screening laboratory studies
At least two of the following: resting tremor, cogwheel rigidity, bradykinesia, and postural reflex impairment

Exclusion Criteria:

Pregnancy
Significant medical disease including abnormalities found on screening
No Results Posted